M
Mayumi Tamada
Researcher at Keio University
Publications - 7
Citations - 1627
Mayumi Tamada is an academic researcher from Keio University. The author has contributed to research in topics: CD44 & Cancer cell. The author has an hindex of 6, co-authored 6 publications receiving 1351 citations.
Papers
More filters
Journal ArticleDOI
CD44 Variant Regulates Redox Status in Cancer Cells by Stabilizing the xCT Subunit of System xc− and Thereby Promotes Tumor Growth
Takatsugu Ishimoto,Osamu Nagano,Toshifumi Yae,Mayumi Tamada,Takeshi Motohara,Hiroko Oshima,Masanobu Oshima,Tatsuya Ikeda,Rika Asaba,Hideki Yagi,Takashi Masuko,Takatsune Shimizu,Tomoki Ishikawa,Tomoki Ishikawa,Kazuharu Kai,Eri Takahashi,Yu Imamura,Yoshifumi Baba,Mitsuyo Ohmura,Makoto Suematsu,Hideo Baba,Hideyuki Saya +21 more
TL;DR: It is shown that a CD44 variant (CD44v) interacts with xCT, a glutamate-cystine transporter, and controls the intracellular level of reduced glutathione (GSH).
Journal ArticleDOI
Pyruvate Kinase M2: Multiple Faces for Conferring Benefits on Cancer Cells
TL;DR: Induction of PKM2 is induced translocation into the nucleus, where it activates transcription of various genes by interacting with and phosphorylating specific nuclear proteins, endowing cancer cells with a survival and growth advantage.
Journal ArticleDOI
Modulation of Glucose Metabolism by CD44 Contributes to Antioxidant Status and Drug Resistance in Cancer Cells
Mayumi Tamada,Osamu Nagano,Seiji Tateyama,Mitsuyo Ohmura,Toshifumi Yae,Toshifumi Yae,Takatsugu Ishimoto,Takatsugu Ishimoto,Eiji Sugihara,Nobuyuki Onishi,Takehiro Yamamoto,Hiroshi Yanagawa,Makoto Suematsu,Hideyuki Saya +13 more
TL;DR: It is found that CD44, a cell surface marker for cancer stem cells, interacts with pyruvate kinase M2 (PKM2) and thereby enhances the glycolytic phenotype of cancer cells that are either deficient in p53 or exposed to hypoxia.
Journal ArticleDOI
CD44s regulates the TGF-β-mediated mesenchymal phenotype and is associated with poor prognosis in patients with hepatocellular carcinoma
Kosuke Mima,Hirohisa Okabe,Takatsugu Ishimoto,Hiromitsu Hayashi,Shigeki Nakagawa,Hideyuki Kuroki,Masayuki Watanabe,Toru Beppu,Mayumi Tamada,Osamu Nagano,Hideyuki Saya,Hideo Baba +11 more
TL;DR: It is suggested that CD44s plays a critical role in the TGF-β-mediated mesenchymal phenotype and therefore represents a potential therapeutic target for HCC.
Journal ArticleDOI
Hochuekkito (TJ-41), a Kampo Formula, Ameliorates Cachexia Induced by Colon 26 Adenocarcinoma in Mice
Suzu Yae,Fumiyuki Takahashi,Toshifumi Yae,Takuji Yamaguchi,Rika Tsukada,Kengo Koike,Kunihiko Minakata,Akiko Murakami,Fariz Nurwidya,Motoyasu Kato,Mayumi Tamada,Momoko Yoshikawa,Hiroyuki Kobayashi,Kuniaki Seyama,Kazuhisa Takahashi +14 more
TL;DR: It is suggested that hochuekkito inhibits the production of proinflammatory cytokines, particularly IL-6, by host cells such as macrophages, and may be a promising anticachectic agent for the treatment of patients with cancer.